Usefulness of F-18-fluorodeoxyglucose Positron Emission Tomography to Confirm Suspected Pancreatic Cancer: a Meta-analysis
Overview
Oncology
Affiliations
Introduction: Pancreatic cancer is among the five most lethal malignancies in the world. Unfortunately, many malignant tumors go undetected by the current primary diagnostic tools. (18)FDG-PET and (18)FDG-PET/CT might be useful to confirm suspected pancreatic cancer.
Methods: A meta-analysis was performed using all major search engines. Methodological quality of included studies was assessed as well as quality of the PET-protocol. The following pooled estimates served as primary outcome measures: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy.
Results: Thirty-five studies were included. Pooled estimates for (18)FDG-PET were: sensitivity 90%, specificity 76%, PPV 90%, NPV 76% and accuracy 86%. Pooled estimates for (18)FDG-PET/CT were: sensitivity 90%, specificity 76%, PPV 89%, NPV 78% and accuracy 86%. The pooled sensitivity and specificity for (18)FDG-PET to differentiate between pancreatic cancer and chronic pancreatitis were 90% and 84%, respectively.
Conclusion: Both (18)FDG-PET and (18)FDG-PET/CT offer no benefit over the current primary diagnostic tools in diagnosing pancreatic cancer. However, the (18)FDG-PET/CT systems are still improving. We should investigate the sensitivity and specificity of these new systems while reevaluating the tradeoff between false positive and false negative results. Yet, (18)FDG-PET/CT may have a role in the staging of pancreatic cancer, in survival prediction, and may add to other diagnostic information, like histology.
Bugazia D, Al-Najjar E, Esmail A, Abdelrahim S, Abboud K, Abdelrahim A Front Oncol. 2024; 14:1386699.
PMID: 39011469 PMC: 11247645. DOI: 10.3389/fonc.2024.1386699.
The role of endoscopic ultrasound in the detection of pancreatic lesions in high-risk individuals.
Overbeek K, Cahen D, Bruno M Fam Cancer. 2024; 23(3):279-293.
PMID: 38573399 PMC: 11255057. DOI: 10.1007/s10689-024-00380-5.
Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.
Bilreiro C, Andrade L, Santiago I, Marques R, Matos C Eur J Radiol Open. 2024; 12:100553.
PMID: 38357385 PMC: 10864763. DOI: 10.1016/j.ejro.2024.100553.
Li X, Lu N, Lin L, Chen Y, Yang S, Wang H J Nucl Med. 2024; 65(2):206-212.
PMID: 38176719 PMC: 10858376. DOI: 10.2967/jnumed.123.266283.
Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma.
Shen X, Niu N, Xue J J Transl Int Med. 2023; 11(4):322-329.
PMID: 38130635 PMC: 10732496. DOI: 10.2478/jtim-2022-0022.